<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lupus nephritis: Treatment of focal or diffuse lupus nephritis resistant to initial therapy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lupus nephritis: Treatment of focal or diffuse lupus nephritis resistant to initial therapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Lupus nephritis: Treatment of focal or diffuse lupus nephritis resistant to initial therapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ronald J Falk, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Maria Dall'Era, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gerald B Appel, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Glassock, MD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Brad H Rovin, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siobhan M Case, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2179539388"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Treatment of lupus nephritis (LN) varies according to the specific International Society of Nephrology (ISN)/Renal Pathology Society (RPS) histopathologic class as well as other clinical and pathologic features and the prior treatment course of the patient. However, no single regimen is regarded as optimal for all patients with LN, and treatment must be individualized. Combined immunosuppressive therapy is typically indicated in patients with diffuse and focal LN and in many patients with lupus membranous nephropathy.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3056.html" rel="external">"Lupus nephritis: Diagnosis and classification"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3093.html" rel="external">"Lupus nephritis: Therapy of lupus membranous nephropathy"</a>.)</p><p></p><p>Some patients with focal or diffuse LN are truly resistant to initial immunosuppressive treatments despite full adherence with the prescribed regimen. By contrast, a greater number of patients are perceived to have resistant LN.</p><p>The treatment of focal or diffuse LN that is resistant to initial therapy will be reviewed here. The initial and subsequent therapy of focal or diffuse LN, treatment of relapsing focal or diffuse LN, treatment of lupus membranous nephropathy, and treatment of recurrent LN in the transplanted kidney are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3059.html" rel="external">"Lupus nephritis: Initial and subsequent therapy for focal or diffuse lupus nephritis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3093.html" rel="external">"Lupus nephritis: Therapy of lupus membranous nephropathy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/131335.html" rel="external">"Lupus nephritis: Treatment of relapsing focal or diffuse lupus nephritis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3066.html" rel="external">"Kidney transplantation in adults: Issues related to lupus nephritis"</a>.)</p><p></p><p class="headingAnchor" id="H78875788"><span class="h1">ESTABLISHING RESISTANT DISEASE</span><span class="headingEndMark"> — </span>Among patients with focal or diffuse lupus nephritis (LN), resistant disease refers to the failure of initial immunosuppressive therapy to achieve either a complete or partial clinical response. There is no consensus, however, on the definition of complete or partial response in patients with focal or diffuse LN; thus, estimates of resistant disease are variable. Definitions of partial and complete response that are most commonly used incorporate a reduction in urine protein excretion, improvement or stabilization of the serum creatinine, and improvement of the urinary sediment (eg, resolution of hematuria/red cell casts). The development of complete response usually requires a minimum of six months and, in some patients, as long as 12 months or more after the initiation of initial therapy [<a href="#rid1">1-4</a>]. (See  <a class="medical medical_review" href="/d/html/3059.html" rel="external">"Lupus nephritis: Initial and subsequent therapy for focal or diffuse lupus nephritis", section on 'Definitions of response'</a>.)</p><p>Assessment of the patient's response should begin as early as three to four months after initial therapy to determine whether the patient is demonstrating a clinical response to therapy (ie, a reduction in proteinuria, improvement or stabilization of the serum creatinine, improvement of the urinary sediment) (see  <a class="medical medical_review" href="/d/html/3059.html" rel="external">"Lupus nephritis: Initial and subsequent therapy for focal or diffuse lupus nephritis", section on 'Monitoring the response to therapy'</a>). In patients who show signs of improvement, we continue their initial therapy and assess their ongoing response. Lack of any improvement at three to four months should prompt the clinician to suspect that the patient may be resistant to the regimen used for initial therapy. The management of patients suspected of treatment resistance is discussed elsewhere in this topic. (See <a class="local">'Management'</a> below.)</p><p>Truly resistant disease may be less common than previously thought. Perceived resistance, which is more common, is often due to incomplete adherence or nonadherence to the prescribed immunosuppressive regimen or to inadequacy of the prescribed regimen. Nonadherence to medical regimens in patients with systemic lupus erythematosus (SLE) varies widely (3 to 83 percent) depending upon the population studied and the definitions used [<a href="#rid5">5,6</a>]. However, nonadherence is higher in studies using objective measurements of nonadherence [<a href="#rid7">7</a>]. (See <a class="local">'Assessment of patient adherence to therapy'</a> below.)</p><p class="headingAnchor" id="H2236817489"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The first step in the management of the patient suspected of being treatment resistant is to assess the adequacy of the patient's therapeutic regimen and adherence to this initial therapy since nonadherence is frequently the cause of perceived resistance to therapy. (See <a class="local">'Assessment of patient adherence to therapy'</a> below.)</p><p>Diagnosing nonadherence to a medical regimen in patients with lupus nephritis (LN) can be challenging and may require both subjective and objective measurements and a personalized approach to management [<a href="#rid7">7</a>].</p><p>Once nonadherence to therapy has been excluded, our general approach to patients with treatment-resistant focal or diffuse LN depends upon which immunosuppressive regimen was used for initial therapy and is presented below. (See <a class="local">'Approach based on prior initial therapy'</a> below.)</p><p class="headingAnchor" id="H1012259577"><span class="h2">Assessment of patient adherence to therapy</span><span class="headingEndMark"> — </span>All patients with focal or diffuse LN suspected of being resistant to initial therapy should be evaluated for their adherence to therapy. In our clinical experience, many cases of suspected treatment resistance are related to nonadherence rather than actual resistance to immunosuppressive therapy. Multiple factors may contribute to treatment nonadherence among patients with systemic lupus erythematosus (SLE), including adverse effects of medications, social determinants of health (eg, socioeconomic status), inability to afford medications, health literacy, and access [<a href="#rid7">7-11</a>].</p><p>We take the following approach to assessing adherence to therapy:</p><p class="bulletIndent1"><span class="glyph">●</span>We ask open questions, such as "I realize that it is difficult to remember to take your medications every day. On average, how many days per week are you able to take your medications?" We find that this is a nonjudgmental and effective way to elicit this information.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some contributors measure drug levels (eg, blood <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a>, <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a>, or calcineurin inhibitor [CNI] levels). However, drug levels may not reliably reflect long-term adherence, as some patients may only take their medications just prior to the drug level test.</p><p></p><p>If it is determined that nonadherence to therapy is likely contributing to the patient's lack of clinical response to immunosuppressive therapy, we begin by trying to understand the reasons for nonadherence and tailor our approach to the individual patient. As an example, if nonadherence is due to side effects (such as nausea or diarrhea), we would switch to an alternative therapy. If the patient has difficulty remembering to take their medications, we may suggest using a pill box/organizer, setting alarms on their smart phone, or switching to an injectable medication.</p><p>Nonadherence among patients with SLE appears to be common [<a href="#rid8">8-10,12,13</a>], although there are no data on the prevalence of nonadherence specifically among those with LN. In an analysis of 13,429 Medicaid beneficiaries with SLE who were new users of <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a> or immunosuppressive medications, 79 percent of new users of hydrochloroquine and 83 percent of new users of immunosuppressive medications were nonadherent to therapy (defined as a medication possession ratio [MPR] &lt;80 percent) [<a href="#rid5">5</a>]. Compared with adherence, nonadherence was associated with higher risks of all-cause and SLE-related emergency department visits and hospitalization.</p><p class="headingAnchor" id="H4294453844"><span class="h2">When to repeat a kidney biopsy</span><span class="headingEndMark"> — </span>In patients with focal or diffuse LN not responsive to initial therapy, a repeat kidney biopsy may be useful when a clinician is contemplating a change in immunosuppressive therapy. As an example, the biopsy can help to distinguish active inflammation from chronic changes, particularly in a patient with persistent proteinuria above the target without hematuria, or to exclude an alternative diagnosis. If a decision has already been made to change therapy, a repeat biopsy may be deferred to see how the patient responds to the new therapy.</p><p>General indications for repeat kidney biopsy in patients with LN are discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3056.html" rel="external">"Lupus nephritis: Diagnosis and classification", section on 'When to repeat the biopsy'</a>.)</p><p class="headingAnchor" id="H3834396376"><span class="h2">Approach based on prior initial therapy</span><span class="headingEndMark"> — </span>Once nonadherence to initial therapy has been excluded or resolved (see <a class="local">'Assessment of patient adherence to therapy'</a> above), the approach to patients who are considered resistant to initial therapy (ie, who have ongoing clinical or histologic evidence of active nephritis) varies with the agent used for initial therapy (eg, <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil [MMF] or <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>) and the severity of disease  (<a class="graphic graphic_algorithm graphicRef134592" href="/d/graphic/134592.html" rel="external">algorithm 1</a>).</p><p>Our approach is generally consistent with recommendations made by the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Glomerulonephritis, the Joint European Alliance of Associations for Rheumatology (formerly known as European League Against Rheumatism)/European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA), and the American College of Rheumatology [<a href="#rid14">14-16</a>].</p><p class="headingAnchor" id="H3345805239"><span class="h3">Patients resistant to MMF</span><span class="headingEndMark"> — </span>For patients with focal or diffuse LN who are resistant to <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF) plus glucocorticoids as initial therapy, we suggest switching to intravenous <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> plus glucocorticoids. Reasonable alternatives include combination therapy with cyclophosphamide plus <a class="drug drug_general" data-topicid="16479" href="/d/drug information/16479.html" rel="external">belimumab</a> or continuation of MMF with the addition of either a CNI (<a class="drug drug_general" data-topicid="130589" href="/d/drug information/130589.html" rel="external">voclosporin</a>, <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>, or <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>) or <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>; however, there are minimal data to support the use of these regimens in patients with resistant disease. The choice among these regimens depends upon several factors, including clinician and patient preference, drug availability and cost, toxicity, and tolerability. There is no evidence directly comparing these regimens in the treatment of patients with resistant focal or diffuse LN, and this approach is largely based upon our clinical experience and expert opinion [<a href="#rid14">14-16</a>]. The regimens are the same as those used for initial therapy. (See  <a class="medical medical_review" href="/d/html/3059.html" rel="external">"Lupus nephritis: Initial and subsequent therapy for focal or diffuse lupus nephritis", section on 'Cyclophosphamide-based regimen'</a> and  <a class="medical medical_review" href="/d/html/3059.html" rel="external">"Lupus nephritis: Initial and subsequent therapy for focal or diffuse lupus nephritis", section on 'Combination regimens'</a>.)</p><p>Some experts would add a CNI to MMF in patients with stable kidney function who continue to have persistent proteinuria above the target while on MMF and also receiving a renin-angiotensin inhibitor. Repeat kidney biopsy may also be appropriate in such patients to confirm that the residual proteinuria correlates with ongoing immunologic activity and not chronic changes. Patients with evidence of necrotizing glomerulonephritis on biopsy may be preferably treated with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, either alone or in combination with <a class="drug drug_general" data-topicid="16479" href="/d/drug information/16479.html" rel="external">belimumab</a>.</p><p>There are no studies that have examined the efficacy of <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> among patients who are resistant to therapy with MMF. However, indirect evidence for the use of cyclophosphamide comes from large, multinational, randomized trials showing efficacy in patients with severe (but not necessarily resistant) LN. (See  <a class="medical medical_review" href="/d/html/3059.html" rel="external">"Lupus nephritis: Initial and subsequent therapy for focal or diffuse lupus nephritis", section on 'Initial therapy with mycophenolate or cyclophosphamide'</a>.)</p><p>There is limited evidence to suggest that combination therapy with MMF is effective among MMF-resistant patients [<a href="#rid17">17,18</a>]. In one observational study, <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> (0.075 mg/kg/day) was added to MMF in 17 patients with MMF-resistant class IV (n = 15) or class V (n = 2) LN [<a href="#rid17">17</a>]. After a mean follow-up of 24 months, six patients (35 percent) had a complete response (defined as urinary protein excretion of &lt;0.3 g/day, normal sediment, and normal or stable kidney function), and six patients had a partial response (defined as protein excretion of &lt;2.9 g/day with stable or improved kidney function). Tacrolimus was well tolerated. In another retrospective study, 29 Korean patients were treated with MMF plus tacrolimus after either not achieving a complete response to initial treatment with MMF or <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> after 12 months or after achieving a complete response at 12 months but then having a relapse [<a href="#rid19">19</a>]. Fifteen and 26 percent of patients treated with combination therapy achieved a complete response after 6 and 12 months, respectively.</p><p class="headingAnchor" id="H2169059439"><span class="h3">Patients resistant to cyclophosphamide</span><span class="headingEndMark"> — </span>For patients with focal or diffuse LN who are resistant to <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> plus glucocorticoids as initial therapy, we suggest treatment with MMF plus glucocorticoids. Reasonable alternatives include combination therapy with MMF plus either a CNI (<a class="drug drug_general" data-topicid="130589" href="/d/drug information/130589.html" rel="external">voclosporin</a>, <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>, or <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>), <a class="drug drug_general" data-topicid="16479" href="/d/drug information/16479.html" rel="external">belimumab</a>, or <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>; however, there are minimal data to support the use of these regimens in patients with resistant disease. The choice among these regimens depends upon several factors, including clinician and patient preference, drug availability and cost, toxicity, and tolerability. There is no evidence directly comparing these regimens in the treatment of patients with resistant focal or diffuse LN, and this approach is largely based upon our clinical experience and expert opinion [<a href="#rid14">14-16</a>]. The regimens are the same as those used for initial therapy. (See  <a class="medical medical_review" href="/d/html/3059.html" rel="external">"Lupus nephritis: Initial and subsequent therapy for focal or diffuse lupus nephritis", section on 'Mycophenolate-based regimen'</a>.)</p><p>Limited data from small case series suggest that MMF may be effective in treating patients who are resistant to <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> [<a href="#rid20">20-23</a>]. As an example, in one series of 12 patients who were resistant to or relapsed following cyclophosphamide and treated with MMF for a mean of 13 months, proteinuria decreased and serum creatinine was stable or decreased in 10 patients [<a href="#rid21">21</a>]. Also, the urine sediment returned to normal in six patients. In another study of 14 patients with diffuse LN who did not respond to initial therapy with cyclophosphamide, treatment with MMF resulted in complete remission in 10 patients and partial remission in four patients [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H132147693"><span class="h3">Patients resistant to both cyclophosphamide- and MMF-based regimens</span><span class="headingEndMark"> — </span>For patients with focal or diffuse LN who have failed treatment with or are unable to tolerate both cyclophosphamide- and <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF)-based regimens (ie, with or without a CNI [<a class="drug drug_general" data-topicid="130589" href="/d/drug information/130589.html" rel="external">voclosporin</a>, <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>, or <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>] or <a class="drug drug_general" data-topicid="16479" href="/d/drug information/16479.html" rel="external">belimumab</a>), we treat with a rituximab-based regimen. Although the addition of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> to MMF as initial therapy has not been shown to improve clinical outcomes in one randomized trial [<a href="#rid1">1</a>], observational studies suggest a possible benefit in patients with resistant disease. Various rituximab-based regimens have been utilized in open-label studies and case series, including rituximab plus MMF, rituximab plus cyclosporine, or rituximab plus <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>. Importantly, none of these regimens have demonstrated efficacy in randomized controlled trials. For rituximab dosing, we typically use the dose regimen used for rheumatoid arthritis or membranous nephropathy, administering 1 g of rituximab initially followed 14 days later by another 1 g dose. (See  <a class="medical medical_review" href="/d/html/7501.html" rel="external">"Rituximab: Principles of use and adverse effects in rheumatoid arthritis"</a> and  <a class="medical medical_review" href="/d/html/3051.html" rel="external">"Membranous nephropathy: Treatment and prognosis", section on 'Rituximab'</a>.)</p><p>While there are no data from randomized trials, favorable results with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> have been noted in a systematic review of observational studies and case reports of LN that is resistant to either <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> or MMF [<a href="#rid24">24-30</a>]. Data supporting rituximab are more limited in patients who are resistant to both cyclophosphamide and MMF and in those who cannot tolerate either drug:</p><p class="bulletIndent1"><span class="glyph">●</span>The largest reported experience included 22 patients with focal or diffuse LN who had persistent disease activity despite a variety of immunosuppressive drugs; most had been treated with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> (11 patients) or MMF (12 patients) as well as other drugs (eg, <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>) [<a href="#rid25">25</a>]. <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> (0.5 to 1 g on days 1 and 15) was added to the existing immunosuppressive regimen. Three months after the administration of rituximab, five patients had a complete response (normal serum creatinine, inactive urine sediment, and protein excretion of &lt;500 mg/day), and seven patients had a partial response (&gt;40 percent improvement in kidney parameters). The effect of rituximab in those patients who were initially treated with cyclophosphamide was not specifically noted.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> was also assessed in a series of 20 patients with diffuse LN (15 patients) or lupus membranous nephropathy (5 patients), all but two of whom had resistant or relapsing disease [<a href="#rid26">26</a>]. Fifteen patients had been previously treated with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>. Rituximab was given at a dose of 375 mg/m<sup>2</sup> weekly for four weeks. Ten patients received additional doses of rituximab as maintenance therapy because of an increase in B cell count. At a mean follow-up of 22 months, 5 of the 15 patients with diffuse LN achieved complete response, defined as protein excretion of &lt;500 mg/day, absence of hematuria, and an increase in estimated glomerular filtration rate (eGFR) by at least 50 percent. In addition, five patients had a partial response, defined as a decrease in protein excretion by at least 50 percent and stabilization of the eGFR.</p><p></p><p class="headingAnchor" id="H2152165101"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Patients with treatment-resistant focal or diffuse lupus nephritis (LN) have a worse kidney prognosis than patients who respond. This is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3059.html" rel="external">"Lupus nephritis: Initial and subsequent therapy for focal or diffuse lupus nephritis", section on 'Long-term outcomes'</a>.)</p><p class="headingAnchor" id="H2475010760"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110250.html" rel="external">"Society guideline links: Glomerular disease in adults"</a> and  <a class="medical medical_society_guidelines" href="/d/html/110740.html" rel="external">"Society guideline links: Systemic lupus erythematosus"</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition of resistant disease</strong> – Among patients with focal or diffuse lupus nephritis (LN), resistant disease refers to the failure of initial immunosuppressive therapy to achieve either a complete or partial clinical response. There is no consensus on the definition of complete or partial response; however, definitions that are most commonly used incorporate a reduction in urine protein excretion, improvement or stabilization of the serum creatinine, and improvement of the urinary sediment. (See <a class="local">'Establishing resistant disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Assessment of patient adherence</strong> – The first step in the management of the patient suspected of being treatment resistant is to assess the adequacy of the patient's therapeutic regimen and adherence to this initial therapy since nonadherence is frequently the cause of perceived resistance to therapy. (See <a class="local">'Assessment of patient adherence to therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Approach based on prior initial therapy</strong> – Once nonadherence to therapy has been excluded or resolved, our general approach to patients with treatment-resistant focal or diffuse LN depends upon which immunosuppressive regimen was used for initial therapy  (<a class="graphic graphic_algorithm graphicRef134592" href="/d/graphic/134592.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Resistant to </strong><a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a><strong> mofetil (MMF)</strong> – For patients with focal or diffuse LN who are resistant to MMF plus glucocorticoids as initial therapy, we suggest switching to intravenous <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> plus glucocorticoids (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Reasonable alternatives include combination therapy with cyclophosphamide plus <a class="drug drug_general" data-topicid="16479" href="/d/drug information/16479.html" rel="external">belimumab</a> or continuation of MMF with the addition of either a calcineurin inhibitor (CNI; <a class="drug drug_general" data-topicid="130589" href="/d/drug information/130589.html" rel="external">voclosporin</a>, <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>, or <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>) or <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>. (See <a class="local">'Patients resistant to MMF'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Resistant to </strong><a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> – For patients with focal or diffuse LN who are resistant to cyclophosphamide plus glucocorticoids as initial therapy, we suggest treatment with MMF plus glucocorticoids (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Reasonable alternatives include combination therapy with MMF plus either a CNI (<a class="drug drug_general" data-topicid="130589" href="/d/drug information/130589.html" rel="external">voclosporin</a>, <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>, or <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>), <a class="drug drug_general" data-topicid="16479" href="/d/drug information/16479.html" rel="external">belimumab</a>, or <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>. (See <a class="local">'Patients resistant to cyclophosphamide'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Resistant to both </strong><a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a><strong> and MMF</strong> – For patients with focal or diffuse LN who have failed treatment with or are unable to tolerate both cyclophosphamide- and MMF-based regimens (ie, with or without a CNI [<a class="drug drug_general" data-topicid="130589" href="/d/drug information/130589.html" rel="external">voclosporin</a>, <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>, or <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>] or <a class="drug drug_general" data-topicid="16479" href="/d/drug information/16479.html" rel="external">belimumab</a>), we treat with a rituximab-based regimen. A rituximab-based regimen refers to the use of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> in combination with a CNI, MMF, or cyclophosphamide. (See <a class="local">'Patients resistant to both cyclophosphamide- and MMF-based regimens'</a> above.)</p><p></p><p class="headingAnchor" id="H1716074"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Peter H Schur, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64:1215.</a></li><li><a class="nounderline abstract_t">Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20:1103.</a></li><li><a class="nounderline abstract_t">Furie R, Rovin BH, Houssiau F, et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med 2020; 383:1117.</a></li><li><a class="nounderline abstract_t">Rovin BH, Teng YKO, Ginzler EM, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2021; 397:2070.</a></li><li><a class="nounderline abstract_t">Feldman CH, Yazdany J, Guan H, et al. Medication Nonadherence Is Associated With Increased Subsequent Acute Care Utilization Among Medicaid Beneficiaries With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken) 2015; 67:1712.</a></li><li><a class="nounderline abstract_t">Costedoat-Chalumeau N, Pouchot J, Guettrot-Imbert G, et al. Adherence to treatment in systemic lupus erythematosus patients. Best Pract Res Clin Rheumatol 2013; 27:329.</a></li><li><a class="nounderline abstract_t">Costedoat-Chalumeau N, Houssiau FA. Improving medication adherence in patients with lupus nephritis. Kidney Int 2021; 99:285.</a></li><li><a class="nounderline abstract_t">Koneru S, Shishov M, Ware A, et al. Effectively measuring adherence to medications for systemic lupus erythematosus in a clinical setting. Arthritis Rheum 2007; 57:1000.</a></li><li><a class="nounderline abstract_t">Daleboudt GM, Broadbent E, McQueen F, Kaptein AA. Intentional and unintentional treatment nonadherence in patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2011; 63:342.</a></li><li><a class="nounderline abstract_t">Julian LJ, Yelin E, Yazdany J, et al. Depression, medication adherence, and service utilization in systemic lupus erythematosus. Arthritis Rheum 2009; 61:240.</a></li><li><a class="nounderline abstract_t">Mosley-Williams A, Lumley MA, Gillis M, et al. Barriers to treatment adherence among African American and white women with systemic lupus erythematosus. Arthritis Rheum 2002; 47:630.</a></li><li><a class="nounderline abstract_t">Marengo MF, Waimann CA, de Achaval S, et al. Measuring therapeutic adherence in systemic lupus erythematosus with electronic monitoring. Lupus 2012; 21:1158.</a></li><li><a class="nounderline abstract_t">Koneru S, Kocharla L, Higgins GC, et al. Adherence to medications in systemic lupus erythematosus. J Clin Rheumatol 2008; 14:195.</a></li><li><a class="nounderline abstract_t">Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 2020; 79:713.</a></li><li><a class="nounderline abstract_t">Rovin BH, Caster DJ, Cattran DC, et al. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2019; 95:281.</a></li><li><a class="nounderline abstract_t">Anders HJ, Lei Y, Rovin BH. Induction and maintenance therapy of lupus nephritis: an obituary. Kidney Int 2021; 99:288.</a></li><li><a class="nounderline abstract_t">Cortés-Hernández J, Torres-Salido MT, Medrano AS, et al. Long-term outcomes--mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. Nephrol Dial Transplant 2010; 25:3939.</a></li><li><a class="nounderline abstract_t">Lanata CM, Mahmood T, Fine DM, Petri M. Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis. Lupus 2010; 19:935.</a></li><li><a class="nounderline abstract_t">Choi CB, Won S, Bae SC. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis. Lupus 2018; 27:1007.</a></li><li><a class="nounderline abstract_t">Karim MY, Pisoni CN, Ferro L, et al. Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy. Rheumatology (Oxford) 2005; 44:1317.</a></li><li><a class="nounderline abstract_t">Dooley MA, Cosio FG, Nachman PH, et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 1999; 10:833.</a></li><li><a class="nounderline abstract_t">Glicklich D, Acharya A. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am J Kidney Dis 1998; 32:318.</a></li><li><a class="nounderline abstract_t">Kapitsinou PP, Boletis JN, Skopouli FN, et al. Lupus nephritis: treatment with mycophenolate mofetil. Rheumatology (Oxford) 2004; 43:377.</a></li><li><a class="nounderline abstract_t">Weidenbusch M, Römmele C, Schröttle A, Anders HJ. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant 2013; 28:106.</a></li><li><a class="nounderline abstract_t">Vigna-Perez M, Hernández-Castro B, Paredes-Saharopulos O, et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006; 8:R83.</a></li><li><a class="nounderline abstract_t">Melander C, Sallée M, Trolliet P, et al. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol 2009; 4:579.</a></li><li><a class="nounderline abstract_t">Fra GP, Avanzi GC, Bartoli E. Remission of refractory lupus nephritis with a protocol including rituximab. Lupus 2003; 12:783.</a></li><li><a class="nounderline abstract_t">Thatayatikom A, White AJ. Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun Rev 2006; 5:18.</a></li><li><a class="nounderline abstract_t">Camous L, Melander C, Vallet M, et al. Complete remission of lupus nephritis with rituximab and steroids for induction and rituximab alone for maintenance therapy. Am J Kidney Dis 2008; 52:346.</a></li><li><a class="nounderline abstract_t">Davies RJ, Sangle SR, Jordan NP, et al. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis. Lupus 2013; 22:574.</a></li></ol></div><div id="topicVersionRevision">Topic 3092 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22231479" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19369404" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32937045" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33971155" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26097166" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Medication Nonadherence Is Associated With Increased Subsequent Acute Care Utilization Among Medicaid Beneficiaries With Systemic Lupus Erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24238690" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Adherence to treatment in systemic lupus erythematosus patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33509345" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Improving medication adherence in patients with lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17665465" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Effectively measuring adherence to medications for systemic lupus erythematosus in a clinical setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21120967" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Intentional and unintentional treatment nonadherence in patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19177526" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Depression, medication adherence, and service utilization in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12522837" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Barriers to treatment adherence among African American and white women with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22588588" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Measuring therapeutic adherence in systemic lupus erythematosus with electronic monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18636020" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Adherence to medications in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32220834" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30665569" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33509346" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Induction and maintenance therapy of lupus nephritis: an obituary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20538787" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Long-term outcomes--mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20388722" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29448881" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16049051" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10203368" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Mycophenolate mofetil therapy in lupus nephritis: clinical observations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9708620" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14963204" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Lupus nephritis: treatment with mycophenolate mofetil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22764193" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16677395" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19261822" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14596429" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Remission of refractory lupus nephritis with a protocol including rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16338207" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Rituximab: a promising therapy in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18572292" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Complete remission of lupus nephritis with rituximab and steroids for induction and rituximab alone for maintenance therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23632989" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
